SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital (“Vector”), a leading private equity firm specializing in transformational investments in established technology businesses, today announced it has ...
Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth ...
Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...
SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital, a leading private equity firm specializing in transformational investments in established technology businesses, today announced its investment in ...
The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...
Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More The race to develop the best search engine technology heated up again ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results